Navigation Links
Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process
Date:3/11/2010

THOUSAND OAKS, Calif., March 11 /PRNewswire/ -- Bone Biologics, Inc. announced today that it has received a US Patent Office Notice of Allowance of patent claims which strongly protects the methods of expressing, secreting, and purifying the NELL-1 sequence of the UCB-1 recombinant protein wherein the mammalian cell line comprises a Chinese hamster ovary (CHO) cell. This patent continues the creation of a patent portfolio for musculoskeletal applications of manufacturing and use in bone regeneration and repair as well as cartilage regeneration and repair.  

Bone Biologics has been developing the protein as a platform technology since 2004, leveraging the previous ten years of research in the lab performed by the company's founding scientists at UCLA.  The mechanism of action is not only identified as to how it works, but why, through this exhaustive research effort. This platform technology is combined with DBX® demineralized bone matrix, to promote bone growth in spinal fusion. DBX® is a product of the Musculoskeletal Transplant Foundation, a Bone Biologics partner.  

The platform technology will be subject to the FDA review and approval process, including clinical trials.  It is not currently approved for use in humans.    

Bruce A. Hazuka, President and CEO of Bone Biologics, Inc. said, "This patent issuance is a significant milestone in our efforts to realize the full potential of the UCB-1 protein as a platform technology. We very much appreciate the continued support of MTF on this project."

"We are pleased to continue our partnership with Bone Biologics," noted Bruce Stroever, CEO of MTF. "This latest patent issuance is a clear sign that the company is continuing to make very good progress toward FDA approval and commercialization of an important product."

Musculoskeletal Transplant Foundation

MTF is a non-profit service organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. In 2009, MTF distributed over 415,000 tissue grafts.

Bone Biologics, Inc.

Bone Biologics is a convergence biotechnology company focused in the orthobiologics space.  The company was founded in 2004 by the research scientists who had identified and validated the product in the lab over the previous ten years.  The acquisition of an exclusive worldwide license from UCLA and the both the financing and strategic support from MTF was the genesis of the development of this recombinant protein.

For information: Bruce A. Hazuka/Bone Biologics/818-324-2742

SOURCE Bone Biologics, Inc.

Back to top
'/>"/>
SOURCE Bone Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clive Dix Appointed as Chairman of Crescendo Biologics
2. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
3. PhRMA Statement Supporting Fair Incentives for Biologics Innovation
4. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
5. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
6. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
7. Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
8. Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix
9. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
10. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
11. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , February 5, 2016 ... market research report "Fetal (Labor & Delivery) and Neonatal ... Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, CPAP, Capnograph, ... MarketsandMarkets, This report studies the global market over the ... estimated at USD 6.28 Billion in 2015 and is ...
(Date:2/5/2016)... , February 4, 2016 France ... Spain , UK, and Israel ). It ... 1, 2, and 3 GD, segmented by age and sex in these ... epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing ... France , Germany , Italy ...
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Edwards Lifesciences ... patient-focused innovations for structural heart disease and critical care ... accelerated share repurchase (ASR) agreement with Morgan Stanley & ... stock.  This repurchase is part of the Company,s previously ... the Company,s common stock.  --> ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
(Date:2/5/2016)... ... 2016 , ... Colorize is a web theme package created exclusively ... using Colorize's dynamic moving camera. Colorize is perfect for personal and web related videos ... with 1 to 5 focus points per scene, stage floor scene presets that are ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... for Patients with Rare Diseases, a continuing medical education (CME) event presented by ... first of its kind—and a first for ACCORD, whose mission is to provide ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... that Medicare San Luis Obispo users can expect to see in 2016. To view ... two most significant changes will directly impact many San Luis Obispo seniors who rely ...
(Date:2/4/2016)... ... February 04, 2016 , ... American Addiction Centers (AAC) ... start of Project HoldSpace. Through the partnership, the two organizations seek to tackle ... between the ages of 13 and 18. Currently focused on Ohio schools, the ...
Breaking Medicine News(10 mins):